X0306 4 2017-11-08 0 0001174940 ORAGENICS INC OGEN 0001234879 KOSKI FAMILY LP 3525 TURTLE CREEK BOULEVARD, UNIT 19-B DALLAS TX 75219 0 0 1 0 0001234880 KOSKI ROBERT C 7362 HAWKINS ROAD SARASOTA FL 34241 1 0 1 0 0001234881 KOSKI THOMAS L 4995 ASHLEY PARKWAY SARASOTA FL 34241 0 0 1 0 0001234878 KOSKI CHRISTINE L 3525 TURTLE CREEK BOULDEVARD, UNIT 19-B DALLAS TX 75219 0 0 1 0 0001234877 KOSKI BEVERLY 3525 TURTLE CREEK BOULDEVARD, UNIT 19-B DALLAS TX 75219 0 0 1 0 Common Stock 12864822 D Common Stock 1572523 D Common Stock 1087878 D Common Stock 519666 D Common Stock 20000 I By Koski Management, Inc. Common Stock 530851 I By Trusts Series B Convertible Preferred Stock 0.25 2017-11-08 4 J 0 1500000 0.00 A Common Stock 3000000 3000000 D Common Stock Warrant 0.31 2017-11-08 4 J 0 2419355 0.31 A 2018-05-08 2024-11-08 Common Stock 2419355 5419355 D Shares owned directly by Koski Family Limited Partnership ("KFLP"). Shares owned indirectly by the KFLP general partners: Koski Management, Inc. (solely owned by Beverly Koski), Christine L. Koski, Robert C. Koski and Thomas L. Koski, each of whom is a general partner of the partnership or the controlling person of a corporate general partner of the partnership. Each reporting person disclaims beneficial ownership of all indirectly owned securities in excess of such reporting person's pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner for purposes of Section 16 or any other purpose. Shares owned directly by Christine L. Koski. Shares owned directly by Robert C. Koski, a director of the Company. Shares owned directly by Thomas L. Koski. Shares owned indirectly by Beverly Koski (through Koski Management, Inc.). Shares owned by trusts of which Mr. Robert C. Koski is sole trustee. Such trusts are as follows: the Robert Clayton Koski Trust for the benefit of Anthony James Hunter (100,000 shares); the Robert Clayton Koski Trust for the benefit of Hunter Buchanan Koski (100,000 shares); the Robert Clayton Koski Trust for the benefit of Clayton Ward Bennett (100,000 shares); the Robert Clayton Koski Trust for the benefit of Robert Edward Koski (100,000 shares); and the Robert Clayton Koski Trust for the benefit of Elyse Margaux Koski (97,666 shares). Mr. Koski disclaims beneficial ownership of the shares held by the trusts except to the extent of any pecuniary interest. On November 8, 2017 the Company issued to the KFLP 1,500,000 shares of Series B Preferred Stock at a purchase price of $0.50 per share which are convertible into 3,000,000 shares of the Company's Common Stock, based on a conversion ratio of one share of Series B Preferred Stock into two shares of common stock. The purchase price per share represented by the shares of common stock the Series B Preferred Stock is convertible into equates to $0.25 per share. The Series B Convertible Preferred Stock will be convertible into shares of common stock commencing on the effective date of shareholder approval and has no expiration date. On November 8, 2017, the Company issued to the KFLP in the private placement a warrant to purchase 2,419,355 shares of Common Stock. The Warrant has a term of seven years from the date of issuance, are non-exercisable until 6 months after issuance, and have an exercise price of $0.31 per share. The exercisability of the Warrant into shares of common stock is also subject to shareholder approval. /s/ Mark A. Catchur, as Attorney-in-Fact for CHRISTINE L. KOSKI, BEVERLY KOSKI, KOSKI FAMILY LIMITED PARTNERSHIP, ROBERT C. KOSKI AND THOMAS L. KOSKI 2017-11-13